Varicella immunity in vaccinated healthcare workers

Journal of Clinical Virology

Volumn 57, Issue 2, 2013, Pages 109-114

  Behrman, Amy ^a   Lopez, Adriana S ^b   Chaves, Sandra S ^b   Watson, Barbara M ^c,d   Schmid, D Scott ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adult immunization; Cell medicated immunity; Chickenpox; Healthcare workers; Varicella

Indexed keywords

CHICKENPOX VACCINE; CYTOKINE; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CYTOKINE PRODUCTION; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; TREATMENT RESPONSE; VACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CHICKENPOX; CHICKENPOX VACCINE; CROSS INFECTION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH PERSONNEL; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84877000067     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.01.015     Document Type: Article

References (42)

1. Façanha M.C., Monroe A.C. Occupational and nosocomial transmission of varicella. Braz J Infect Dis 2006, 10:156-158.
2. Behrman A., Schmid S., Crivaro A., Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. Infect Control Hosp Epidemiol 2003, 24:202-206.
3. Meyers J.D., MacQuarrie M.B., Merigan T.C., Jennison M.H. Nosocomial varicella. Part I. Outbreak in oncology patients at a children's hospital. West J Med 1979, 130:196-199.
4. Hyams P.J., Stuewe M.C., Heitzer V. Herpes zoster causing varicella (chickenpox) in hospital employees: cost of a casual attitude. Am J Infect Control 1984, 12:2-5.
5. Krasinski K., Holzman R.S., LaCouture R., Florman A. Hospital experience with varicella-zoster virus. Infect Control 1986, 7:312-316.
6. Haiduven-Griffiths D., Fecko H. Varicella in hospital personnel: a challenge for the infection control practitioner. Am J Infect Control 1987, 15:207-211.
7. Weber D.J., Rutala W.A., Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988, 78:19-23.
8. Galil K., Brown C., Lin F., Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J 2002, 21:931-935.
9. Boelle P.Y., Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002, 129:599-606.
10. Fairley C.K., Miller E. Varicella-zoster virus epidemiology - a changing scene?. J Infect Dis 1996, 174(Suppl. 3):S314-S319.
11. Guess H.A., Broughton D.D., Melton L.J., Kurland L.T. Population-based studies of varicella complications. Pediatrics 1986, 78:723-727.
12. Choo P.W., Donahue J.G., Manson J.E., Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995, 172:706-712.
13. Centers for Disease Control and Prevention Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007, 56(RR-4):1-38.
14. Kuter B.J., Ngai A., Patterson C.M., Staehle B.O., Cho I., Matthews H., et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995, 13:967-972.
15. Saiman L., LaRussa P., Steinberg S.P., Zhou J., Baron K., Whittler S., et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001, 22:279-283.
16. Gershon A.A., Steinberg S.P., LaRussa P., Ferrara A., Hammerschlag M., Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988, 158:132-137.
17. Gershon A.A., Steinberg S.P. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institution of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990, 161:661-666.
18. Ampofo K., Saiman L., LaRussa P., Steinberg S., Annunziato P., Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 2002, 34:774-779.
19. Seward J.F., Zhang J.X., Maupin T.J., Mascola L., Jumaan A.O. Contagiousness of varicella in vaccinated persons: a household contact study. JAMA 2004, 292:704-708.
20. Wasmuth E.H., Miller W.J. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990, 32:189-193.
21. Provost P.J., Krah D.L., Kuter B.J., Morton D.H., Schofield T.L., Wasmuth E.H., et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991, 9:111-116.
22. Weinmann S., Chun C., Mullooly J.P., Riedlinger K., Houston H., Loparev V.N., et al. Laboratory diagnosis and characteristics of breakthrough varicella in children. J Infect Dis 2008, 197:S132-S138.
23. Metz C.E. Basic principles of ROC analysis. Semin Nucl Med 1978, 8:283-298.
24. MacNeil A., Reynolds M.G., Carroll D.S., Karem K., Braden Z., Lash R., et al. Monkeypox or varicella? Lessons from a rash outbreak investigation in the Republic of the Congo. Am J Trop Med Hyg 2009, 80:503-507.
25. Vollset S.E. Confidence intervals for a binomial proportion. Stat Med 1993, 12:809-824.
26. Kontio M., Jokinen S., Paunio M., Peltola H., Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 2012, 206:1542-1548.
27. Steinberg S.P., Gershon A.A. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol 1991, 29:1527-1529.
28. Breuer J., Schmid D.S., Gershon A.A. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 2008, 197(Suppl. 2):S147-S151.
29. Maple P.A., Gray J., Breuer J., Kafatos G., Parker S., Brown D. Performance of a time-resolved fluorescent immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol 2006, 13:214-218.
30. Hayward A.R., Pontesilli O., Herberger M., Laszlo M., Levin M. Specific lysis of varicella-zoster virus-infected B lymphoblasts by human T cells. J Virol 1986, 58:179-184.
31. Sharp M., Terada K., Wilson A., Nader S., Kinchington P.E., Hay J., et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 1992, 165:852-858.
32. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003, 188:1336-1344.
33. Jenkins D.E., Redman R.L., Lam E.M., Liu C., Lin I., Arvin A.M. Interleukin (IL)-10, IL-12, and interferon-γ production in primary and memory responses to varicella-zoster virus. J Infect Dis 1998, 178:940-948.
34. Sadaoka K., Okamoto S., Gomi Y., Tanimoto T., Ishikawa T., Yoshikawa T., et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008, 198:1327-1333.
35. Zhang Y., Cosyns M., Levin M.J., Hayward A.R. Cytokine production in varicella-zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Med 1994, 98:128-133.
36. Yu H.R., Chen R.F., Hong K.C., Bong C.N., Lee W.I., Kuo H.C., et al. IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol 2005, 35:3664-3672.
37. Zhou C., Saxon A., Zhang K. Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification. J Immunol 2003, 170:1887-1893.
38. Vora K.A., Wang L.C., rao S.P., Liu Z.-Y., Majeau G.R., Cutler A.H., et al. Germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003, 171:547-551.
39. Wu Y., El Shikh M.E.M., El Sayed R.M., Best A.M., Szakai A.K., Tew J.G. IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. Int Immunol 2009, 21:745-746.
40. Barreto V., Reina-San-Martin B., Ramiro A.R., McBride K.M., Nussenzweig M.C. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell 2003, 12:501-508.
41. Johnson J.A., Bloch K.C., Dang B.N. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin Infect Dis 2011, 52:907-909.
42. Lopez A.S., Burnett-Hartman A., Nambiar R., Rita L., Owens P., Loparev V.N., et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term facility, West Virginia, 2004. J Infect Dis 2008, 197:646-653.